Close menu




May 18th, 2021 | 07:50 CEST

wallstreet:online, flatexDEGIRO, Facebook: Which broker share is the best?

  • Investments
Photo credits: pixabay.com

When a high savings rate meets rising inflation, the stock market benefits. Even with the outbreak of the pandemic, private investors rushed to take advantage of promising opportunities: gold, hydrogen, electromobility - all these have recently been the trends that have made investors' hearts beat faster. But shares related to the stock market itself are also in demand. Some business models are so mature that they can benefit from the boom in several ways.

time to read: 3 minutes | Author: Nico Popp
ISIN: DE000A2GS609 , DE000FTG1111 , US30303M1027

Table of contents:


    wallstreet:online: Media + Brokerage = Success?

    One example is wallstreet:online. The Company, which many private investors know because of the portal of the same name or the news site Finanznachrichten.de, has been operating brokerage under the Smartbroker brand for more than a year. During its first year, Smartbroker exceeded all expectations and attracted numerous new customers. There were a total of 80,000 in the first year. By the end of 2021, this figure is expected to rise to 200,000 customers. At the same time, the Company has invested in qualified personnel and, in addition to CEO Mattias Hach (previously Comdirect, flatex, ViTrade), has also brought financial expert Roland Nicklaus from the Supervisory Board to the Management Board as CFO. The goal: to address investors even better.

    wallstreet:online is pursuing a business model focusing on the media business and establishing the Smartbroker as an attractive alternative to existing providers. After the already good figures for customer growth, the quality also seems to be convincing: Only recently, Smartbroker received the grade "very good" three times in the broker test of the Handelsblatt. wallstreet:online wants to dovetail its media even better with its brokerage and make it possible for customers to trade directly from forums or articles. It will increase sales and also make the portals even more attractive. The share continues to be on an upward trend, with the price rising like clockwork for more than a year.

    flatexDEGIRO: What is next after 2020?

    The share price of wallstreet:online competitor flatexDEGIRO has also performed well. Most recently, analysts have been concerned about whether trading revenues would continue to be as robust in the second or third quarter as they have been so far. As a result, the share price fell a little. Investors will find out how business is going at the end of June - that is when the Company presents their figures. flatexDEGIRO offers several brokerage brands and focuses primarily on low prices. Furthermore, the Company has developed a core banking system that provides white-label solutions to business customers.

    In 2020, the Company's revenue was EUR 261 million, with profit reaching almost EUR 100 million. Within 2019 and 2020, the Company managed to significantly increase its number of customers, partly due to the acquisition of DEGIRO. In 2020, flatexDEGIRO had around 1.3 million customers. The number of transactions also multiplied last year. Thanks to its full banking license, flatexDEGIRO can offer various financial services. However, whether the value currently still has so much imagination after the growth that has already taken place remains an open question.

    Facebook: This is how it is done!

    Facebook, on the other hand, is also doing good business in the media sector. The Company shows how effectively a media offering can support sales: Users are offered personal ads and content that fits their usage habits. In this way, Facebook has risen into the "Big Five" of the major tech groups. Today, the Company is valued at around EUR 770 billion. The launch of its dating service in the US shows that new products can also be effectively brought to market in Facebook's universe. That this project will be a success seems preprogrammed. Even the Facebook network, which has been a bit out of fashion of late, has recently increased its daily users. And for those who have turned their backs on Facebook, the Company has alternatives in the form of WhatsApp and Instagram.

    Facebook's success is likely to continue. Although tech stocks have been punished a little recently, this is likely to be only a temporary weakness, at least for the big players in the industry - their market position is too big. Smaller companies, on the other hand, can learn from Facebook. wallstreet:online also has many relevant media in its portfolio in the German-speaking region that deal with financial investments. Like Facebook, wallstreet:online could convert the interactions there into new customers and sales for its Smartbroker even more effectively in the future. In the brokerage sector, the wallstreet:online share has the edge because of its promising media holdings.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read